MX2021009337A - Cadenas principales de proteínas de la membrana para la modificación genética de exosomas. - Google Patents
Cadenas principales de proteínas de la membrana para la modificación genética de exosomas.Info
- Publication number
- MX2021009337A MX2021009337A MX2021009337A MX2021009337A MX2021009337A MX 2021009337 A MX2021009337 A MX 2021009337A MX 2021009337 A MX2021009337 A MX 2021009337A MX 2021009337 A MX2021009337 A MX 2021009337A MX 2021009337 A MX2021009337 A MX 2021009337A
- Authority
- MX
- Mexico
- Prior art keywords
- membrane protein
- protein scaffolds
- exosome
- engineering
- exosome engineering
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title abstract 2
- 108010052285 Membrane Proteins Proteins 0.000 title 1
- 102000018697 Membrane Proteins Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente descripción se refiere a proteínas de vesículas exosómicas heterólogas (HEVP, por sus siglas en inglés), exosomas modificados genéticamente que comprenden HEVP, y métodos para preparar y usar estas composiciones, lo que incluye aplicaciones terapéuticas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962801065P | 2019-02-04 | 2019-02-04 | |
US201962801636P | 2019-02-05 | 2019-02-05 | |
US201962851581P | 2019-05-22 | 2019-05-22 | |
PCT/US2020/016629 WO2020163370A1 (en) | 2019-02-04 | 2020-02-04 | Membrane protein scaffolds for exosome engineering |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021009337A true MX2021009337A (es) | 2021-10-13 |
Family
ID=70005693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009337A MX2021009337A (es) | 2019-02-04 | 2020-02-04 | Cadenas principales de proteínas de la membrana para la modificación genética de exosomas. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220249373A1 (es) |
EP (1) | EP3921432A1 (es) |
JP (1) | JP2022519275A (es) |
KR (1) | KR20210142097A (es) |
AU (1) | AU2020217716A1 (es) |
CA (1) | CA3128386A1 (es) |
IL (1) | IL285195A (es) |
MX (1) | MX2021009337A (es) |
SG (1) | SG11202108389QA (es) |
WO (1) | WO2020163370A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021248133A1 (en) | 2020-06-05 | 2021-12-09 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
CN114112867A (zh) * | 2022-01-26 | 2022-03-01 | 天九再生医学(天津)科技有限公司 | 外泌体纯度分析方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2677733A1 (en) | 2007-02-07 | 2008-09-25 | The Regents Of The University Of California | Conjugates of synthetic tlr agonists and uses therefor |
WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
WO2009088401A2 (en) | 2007-09-24 | 2009-07-16 | Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Immunostimulatory combinations of tlr ligands and methods of use |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
DK2313111T3 (da) | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-lignende receptoragonistformuleringer og anvendelse deraf |
AU2010303464B2 (en) | 2009-10-06 | 2014-05-01 | Panacela Labs Llc | Use of toll-like receptor and agonist for treating cancer |
ES2616449T3 (es) | 2010-10-01 | 2017-06-13 | Ventirx Pharmaceuticals, Inc. | Uso terapéutico de un agonista de TLR y terapia de combinación |
GB201609216D0 (en) * | 2016-05-25 | 2016-07-06 | Evox Therapeutics And Isis Innovation Ltd | Exosomes comprising therapeutic polypeptides |
GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
SG11202001008RA (en) | 2017-08-25 | 2020-03-30 | Codiak Biosciences Inc | Preparation of therapeutic exosomes using membrane proteins |
CA3234784A1 (en) * | 2017-11-17 | 2019-05-23 | Lonza Sales Ag | Compositions of engineered exosomes and methods of loading luminal exosome payloads |
-
2020
- 2020-02-04 CA CA3128386A patent/CA3128386A1/en active Pending
- 2020-02-04 SG SG11202108389QA patent/SG11202108389QA/en unknown
- 2020-02-04 JP JP2021545391A patent/JP2022519275A/ja active Pending
- 2020-02-04 EP EP20714311.6A patent/EP3921432A1/en active Pending
- 2020-02-04 AU AU2020217716A patent/AU2020217716A1/en active Pending
- 2020-02-04 MX MX2021009337A patent/MX2021009337A/es unknown
- 2020-02-04 US US17/428,245 patent/US20220249373A1/en active Pending
- 2020-02-04 WO PCT/US2020/016629 patent/WO2020163370A1/en unknown
- 2020-02-04 KR KR1020217026834A patent/KR20210142097A/ko unknown
-
2021
- 2021-07-28 IL IL285195A patent/IL285195A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220249373A1 (en) | 2022-08-11 |
CA3128386A1 (en) | 2020-08-13 |
EP3921432A1 (en) | 2021-12-15 |
AU2020217716A1 (en) | 2021-08-26 |
KR20210142097A (ko) | 2021-11-24 |
SG11202108389QA (en) | 2021-08-30 |
JP2022519275A (ja) | 2022-03-22 |
WO2020163370A1 (en) | 2020-08-13 |
IL285195A (en) | 2021-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
CL2021001776A1 (es) | Péptidos y combinación de péptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres (divisional de la solicitud no. 201702448) | |
MX2021010160A (es) | Preparaciones de membrana bacteriana. | |
MX2020008542A (es) | Composiciones y métodos para el suministro de proteínas membranales. | |
WO2018160754A3 (en) | Inducible monovalent antigen binding protein | |
PH12018500252A1 (en) | Factor ix fusion protiens and methods of making and using same | |
EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
WO2016070166A3 (en) | Messenger una molecules and uses thereof | |
MX2020006612A (es) | Compuesto que funciona como inhibidor de proteína de bromodominio y composición. | |
BR112019002371A2 (pt) | composições farmacêuticas | |
PH12020551019A1 (en) | IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
MX2021009337A (es) | Cadenas principales de proteínas de la membrana para la modificación genética de exosomas. | |
MX2021006925A (es) | Composiciones y metodos heterologos de vacunacion con refuerzo inductor. | |
PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
WO2020023251A8 (en) | Engineered exosomes for medical applications | |
MX2020007945A (es) | Proteinas f del rsv estabilizadas y usos de las mismas. | |
JOP20200323A1 (ar) | طرق لتصنيع تركيبات الأحماض الأمينية | |
WO2018170150A3 (en) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins | |
MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
WO2018161049A8 (en) | Compositions and methods for inducing hiv-1 antibodies | |
MX2020008125A (es) | Composiciones que comprenden berberina. | |
ECSP20083339A (es) | Proteínas inmunodominantes y fragmentos en esclerosis múltiple | |
MX2020010724A (es) | Metodos para preparar composiciones proteicas estables. | |
AU2017254772A1 (en) | Biocompatible Polymeric Membranes | |
WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins |